ClinicalTrials.gov Trials Data - Sponsors, Phases & Sites

Clinical trials from the official ClinicalTrials.gov API v2 as one flat row per trial (or one row per trial site): NCT number, titles, status, phase, study type, conditions, drugs and other interventions, sponsor and collaborators, enrollment, start and completion dates, countries, results flag and primary outcome names.

ClinicalTrials.gov, run by the U.S. National Library of Medicine (NLM), lists more than 600,000 studies from over 200 countries. This Actor reads its official REST API (v2) and returns each study as one flat row that opens cleanly in Excel, Google Sheets or a database. Lists such as conditions or interventions are joined with | instead of nested arrays. You can filter in ways that suit pipeline and competitor research: condition, drug, sponsor, sponsor type (industry, NIH, academic...), phase, status, intervention type, country or region, results posted, and start, primary completion, first posted or last update dates. A site mode returns one row per trial site.

Unofficial tool. Not affiliated with or endorsed by the U.S. National Library of Medicine, NIH, HHS or ClinicalTrials.gov. Data from ClinicalTrials.gov. Every row says when ClinicalTrials.gov processed the data and what this Actor changed (see Attribution and terms). No investigator or contact names, e-mail addresses or phone numbers are returned.

Quick start — verified input

Run on 2026-10-13 on the Apify platform: 25 rows, 2 requests, a few seconds. An empty input {} runs exactly this: the 25 most recently updated studies.

{
  "maxItems": 25
}

Industry-sponsored phase 3 trials in non-small cell lung cancer that are recruiting or about to recruit:

{
  "conditions": ["non-small cell lung cancer"],
  "phases": ["Phase 3"],
  "statuses": ["open"],
  "leadSponsorClasses": ["industry"],
  "maxItems": 200
}

Trial sites in Japan for recruiting phase 3 breast cancer trials (one row per site):

{
  "outputMode": "sites",
  "conditions": ["breast cancer"],
  "phases": ["3"],
  "statuses": ["recruiting"],
  "countries": ["Japan"],
  "maxItems": 500
}

More examples:

• Upcoming readouts for a drug: {"interventions": ["semaglutide"], "primaryCompletionFrom": "2026-01-01", "primaryCompletionTo": "2026-12-31", "sortBy": "primaryCompletion", "sortOrder": "asc", "maxItems": 100}
• Weekly monitor of one sponsor: {"sponsors": ["Pfizer"], "leadSponsorOnly": true, "updatedFrom": "7 days ago", "maxItems": 1000}
• New EU registrations of drug and biologic trials: {"countries": ["EU"], "interventionTypes": ["drug", "biological"], "firstPostedFrom": "30 days ago", "maxItems": 1000}
• Specific trials: {"nctIds": ["NCT04368728", "NCT02993146"]}

Common input mistakes

Wrong	Right	Why
"countries": ["Boston"]	"locations": ["Boston"]	Countries are countries or regions; cities, states and facility names go in locations.
"statuses": ["active"] to get ongoing trials	"statuses": ["ongoing"]	active means "Active, not recruiting". ongoing = recruiting + not yet recruiting + enrolling by invitation + active, not recruiting.
"startDateFrom": "06/15/2024"	"startDateFrom": "2024-06-15"	Slash dates are ambiguous and rejected. YYYY-MM-DD, YYYY-MM, YYYY, today and 30 days ago work.
"conditions": "breast cancer, lung cancer" (one text via the API)	"conditions": ["breast cancer", "lung cancer"]	A single text is split at line breaks and semicolons, not commas, because names such as "Carcinoma, Non-Small-Cell Lung" contain commas.
"phases": ["3"], "studyTypes": ["observational"]	drop one of them	Observational studies have no phase, so this returns 0 rows.
"nctIds": ["NCT123"]	"nctIds": ["NCT00000123"]	An NCT number is NCT + 8 digits. Study URLs also work.

An invalid value stops the run before any request, with a message that names the field and lists the valid values. Plain words are accepted for most lists: "Phase III", "recruiting", "pharma", "vaccine", "US", "South Korea", "EU".

Empty results?

The run ends successfully with 0 rows when nothing matches. Typical causes: a misspelt condition or drug name, a date window with no studies, a phase filter together with observational studies, or a country filter combined with a rare condition. Check RUN_SUMMARY in the key-value store: it shows the exact API query (queryUrls) and how many studies matched (totalMatchingStudies).

What one row contains

Trial rows (outputMode: "trials", the default): nctId, url, briefTitle, officialTitle, acronym, sponsorProtocolId, sponsorProtocolIdWithheld, overallStatus, phase (label such as "Phase 2/3"), phases (codes), studyType, conditions, interventionNames, interventionTypes, interventionOtherNames (brand and code names), leadSponsor, leadSponsorClass, leadSponsorWithheld, collaborators, collaboratorsWithheld, enrollment, enrollmentType (ACTUAL or ESTIMATED), startDate, startDateType, primaryCompletionDate, primaryCompletionDateType, completionDate, completionDateType, firstPostedDate, lastUpdatePostedDate, statusVerifiedDate, hasResults, resultsFirstPostedDate, primaryOutcomes (names of the primary outcome measures), locationCountries, locationCount, ctgovDataTimestamp.

Site rows (outputMode: "sites"): nctId, url, briefTitle, acronym, overallStatus, phase, studyType, conditions, interventionNames, leadSponsor, leadSponsorClass, leadSponsorWithheld, siteNumber, siteCount, facility, facilityWithheld, city, state, country, siteStatus, ctgovDataTimestamp.

Every row also has recordType (trial or site), source, sourceUrl, license and retrievedAt.

Output example (trial row)

{
  "recordType": "trial",
  "nctId": "NCT07060807",
  "url": "https://clinicaltrials.gov/study/NCT07060807",
  "briefTitle": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)",
  "officialTitle": "An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).",
  "acronym": null,
  "sponsorProtocolId": "1022-016",
  "sponsorProtocolIdWithheld": false,
  "overallStatus": "RECRUITING",
  "phase": "Phase 3",
  "phases": "PHASE3",
  "studyType": "INTERVENTIONAL",
  "conditions": "Breast Neoplasms",
  "interventionNames": "Patritumab deruxtecan | Paclitaxel | Nab-paclitaxel | Capecitabine | Pegylated liposomal doxorubicin | Trastuzumab deruxtecan | Rescue Medication",
  "interventionTypes": "BIOLOGICAL | DRUG",
  "interventionOtherNames": "MK-1022 | HER3-DXd | U3-1402 | TAXOL® | ONXAL® | Abraxane® | XELODA® | Doxil® | T-DXd | Enhertu®",
  "leadSponsor": "Merck Sharp & Dohme LLC",
  "leadSponsorClass": "INDUSTRY",
  "leadSponsorWithheld": false,
  "collaborators": "Daiichi Sankyo",
  "collaboratorsWithheld": 0,
  "enrollment": 1000,
  "enrollmentType": "ESTIMATED",
  "startDate": "2025-07-21",
  "startDateType": "ACTUAL",
  "primaryCompletionDate": "2033-07-14",
  "primaryCompletionDateType": "ESTIMATED",
  "completionDate": "2033-07-14",
  "completionDateType": "ESTIMATED",
  "firstPostedDate": "2025-07-11",
  "lastUpdatePostedDate": "2026-10-08",
  "statusVerifiedDate": "2026-10",
  "hasResults": false,
  "resultsFirstPostedDate": null,
  "primaryOutcomes": "Progression Free Survival (PFS) | Overall Survival (OS)",
  "locationCountries": "United States | Argentina | Australia | Brazil | Canada | Chile | China | Colombia | France | Germany | Greece | Hong Kong | Hungary | Israel | Italy | Japan | Mexico | Peru | Poland | South Korea | Spain | Taiwan | Thailand | Turkey (Türkiye) | United Kingdom | Vietnam",
  "locationCount": 201,
  "ctgovDataTimestamp": "2026-10-09T09:00:05",
  "source": "ClinicalTrials.gov (U.S. National Library of Medicine, NIH)",
  "sourceUrl": "https://clinicaltrials.gov/",
  "license": "Source: ClinicalTrials.gov, a U.S. Government database of the National Library of Medicine (NIH). Data processed by ClinicalTrials.gov on 2026-10-09T09:00:05 (API dataTimestamp). Modifications by this Actor: … (full text below)",
  "retrievedAt": "2026-10-12T21:04:20.000Z"
}

Output example (site row)

{
  "recordType": "site",
  "nctId": "NCT07060807",
  "url": "https://clinicaltrials.gov/study/NCT07060807",
  "briefTitle": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)",
  "acronym": null,
  "overallStatus": "RECRUITING",
  "phase": "Phase 3",
  "studyType": "INTERVENTIONAL",
  "conditions": "Breast Neoplasms",
  "interventionNames": "Patritumab deruxtecan | Paclitaxel | Nab-paclitaxel | Capecitabine | Pegylated liposomal doxorubicin | Trastuzumab deruxtecan | Rescue Medication",
  "leadSponsor": "Merck Sharp & Dohme LLC",
  "leadSponsorClass": "INDUSTRY",
  "leadSponsorWithheld": false,
  "siteNumber": 125,
  "siteCount": 201,
  "facility": "Aichi Cancer Center ( Site 3200)",
  "facilityWithheld": false,
  "city": "Nagoya",
  "state": "Aichi-ken",
  "country": "Japan",
  "siteStatus": "RECRUITING",
  "ctgovDataTimestamp": "2026-10-09T09:00:05",
  "source": "ClinicalTrials.gov (U.S. National Library of Medicine, NIH)",
  "sourceUrl": "https://clinicaltrials.gov/",
  "license": "Source: ClinicalTrials.gov, … (same text as above)",
  "retrievedAt": "2026-10-12T21:04:20.000Z"
}

How the filters work

• Within one list a study matches any entry. Different fields are combined with and.
• conditions, interventions, sponsors, keywords and locations use the same search as the ClinicalTrials.gov website, including its synonyms. Each entry can also be a ClinicalTrials.gov search expression (quotes, AND/OR/NOT, AREA[...]).
• phases: a study matches if any of its phases is listed, so a Phase 2/3 study matches PHASE3.
• countries: exact ClinicalTrials.gov country names (for example South Korea, Turkey (Türkiye), Côte d’Ivoire; ISO codes and common names are converted). A study matches if at least one of its sites is in one of the countries. Regions: Europe, European Union, Asia, Africa, North America, Latin America and the Caribbean, South America, Oceania (UN M49 continents; Europe also lists Cyprus) and Middle East. In site mode only the sites in the selected countries are returned.
• Dates: estimated (planned) dates count as well as actual ones. A month or a year means the whole month or year.
• advancedFilter adds your own ClinicalTrials.gov search expression with AND, for example AREA[DesignAllocation]RANDOMIZED. Syntax.

Attribution and terms

The ClinicalTrials.gov Terms and Conditions ask everyone who publishes or distributes ClinicalTrials.gov data to: attribute the source of the data as ClinicalTrials.gov; update the data so that they are current at all times; clearly display the date the data were processed by ClinicalTrials.gov; and state any modifications made to the content, with a complete description of the modifications.

This Actor supports this on every row:

• ctgovDataTimestamp is the date ClinicalTrials.gov processed the data (the dataTimestamp of the API's /api/v2/version). The same date is in license.
• license names the source, gives that date, the complete list of modifications below, the terms link and the disclaimer.
• Complete description of the modifications made by this Actor:

Modifications by this Actor: selected fields of each study record are rearranged into one flat row per study (or one row per study site); lists are joined with " | " and duplicates removed; added fields: url, phase (a label such as "Phase 2/3"), locationCountries, locationCount, siteNumber, siteCount, ctgovDataTimestamp; investigator and contact names, e-mail addresses and phone numbers are not included; sponsor, collaborator and site names that are or may be a person's name are replaced by null (marked by the *Withheld fields): a sponsor or collaborator registered as an individual; a name with a personal title or degree, unless it also names a hospital, university or similar institution (for sponsors classed INDUSTRY, NIH, FED, OTHER_GOV or NETWORK: any organisation); a name without a word that marks an organisation (not applied to those five sponsor classes); for the other sponsor classes, a protocol number that contains words instead of a code is replaced by null (sponsorProtocolIdWithheld); free-text descriptions, eligibility criteria and results data are not included; site addresses are limited to city, state and country; in site rows with a countries filter, sites in other countries are left out. All other values are as published by ClinicalTrials.gov.

Keeping the data current is up to you: re-run before you publish. ClinicalTrials.gov refreshes its data Monday to Friday, generally by 9 a.m. ET. The terms also say: you shall not assert proprietary rights to the data or present it as anything other than a U.S. Government database; you shall not use e-mail addresses from the database for marketing (this Actor returns none); outside the United States the data carry an international copyright, and some data may be subject to third-party copyright. The U.S. Government makes no warranties about the data. The terms apply for as long as you keep the data.

Privacy and GDPR

• No names, e-mail addresses or phone numbers of investigators, study contacts or site contacts. The Actor never even requests those fields from the API.
• Sponsor, collaborator and site names are shown only when they are recognisably an organisation. They are returned as null, with leadSponsorWithheld, collaboratorsWithheld or facilityWithheld set, when the name is registered as an individual (class INDIV), carries a personal title or degree ("Dr.", "Prof.", "MD", "PhD" ...), or contains no word that marks an organisation (such as University, Hospital, Clinic, Institute, Center, Foundation, Group, Society, Ministry, Inc, Ltd, GmbH, and the same words in other languages). A plain personal name, such as a doctor registered as the sponsor of their own study, is therefore not shown. Institutions named after a person, such as "MD Anderson Cancer Center", are kept. The organisation-word test is not applied to sponsors that ClinicalTrials.gov itself classes as INDUSTRY, NIH, FED, OTHER_GOV or NETWORK.
• The rule is deliberately cautious: a few real organisations whose names contain none of these words (for example a hospital listed only by a brand name) are withheld too. In our checks on about 5,900 real site names, fewer than 1 in 100 was withheld. In a sample of 1,000 recently updated trials, 28 of the 31 withheld sponsor and collaborator names were individual people.
• For sponsors outside those five classes, sponsorProtocolId (the sponsor's own protocol number) is returned as null with sponsorProtocolIdWithheld: true when it contains words instead of a code (three or more lowercase letters in a row), because academic protocol numbers sometimes include the investigator's name.
• Site addresses stop at city, state and country (no street, ZIP code or coordinates).
• Public data only. You are responsible for complying with the ClinicalTrials.gov Terms and Conditions and with applicable law, including the GDPR, when you use the data.

How it reads the API

• Only the documented ClinicalTrials.gov API v2 endpoints /api/v2/studies and /api/v2/version are used. The website's search pages and internal endpoints are never called.
• One request at a time, at least 1.5 seconds apart. Retry-After is respected, server errors are retried with a growing wait, and maxApiRequests is a hard budget.
• The first page asks for the total number of matching studies, and the next pages follow the API's nextPageToken. The log and RUN_SUMMARY always say "N of M": nothing is cut off silently. If the run stops early (budget, time limit, an API error), the rows read so far are kept and RUN_SUMMARY.complete is false with a stopReason.
• One request returns up to 1,000 trials in trial mode and up to 100 trials (all their sites) in site mode.
• RUN_SUMMARY (key-value store) also lists notReturnedNctIds (NCT numbers you asked for that are unknown or excluded by the other filters) and how many names and protocol numbers were withheld.

Limits

• maxItems up to 200,000 rows per run; maxApiRequests up to 1,000.
• A large trial can list hundreds of sites, so site mode produces many rows per trial.
• Data are as current as ClinicalTrials.gov's last weekday refresh (shown in ctgovDataTimestamp).

Disclaimer

Unofficial tool. Not affiliated with or endorsed by the U.S. National Library of Medicine, the National Institutes of Health, the U.S. Department of Health and Human Services or ClinicalTrials.gov. The study information is provided by study sponsors and investigators; the U.S. Government does not review or approve the safety and science of all studies listed on ClinicalTrials.gov. This dataset is not medical advice.